Fenfluramine API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Fenfluramine API 458-24-2?
- Description:
- Here you will find a list of producers, manufacturers and traders of Fenfluramine. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Fenfluramine
- Synonyms:
- Fenfluramina , Fenfluraminum
- Cas Number:
- 458-24-2
- DrugBank number:
- DB00574
- Unique Ingredient Identifier:
- 2DS058H2CF
About Fenfluramine
More information about the use of: Fenfluramine. Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997 Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal;it was granted a new FDA approval on June 25, 2020, for treatment of Dravet syndrome patients through the restricted FINTEPLA REMS program.
It is currently sold under the name FINTEPLA® by Zogenix INC.
More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.
